Home Newsfeeds UBS Maintains Buy on CareMax, Lowers Price Target to $6

UBS Maintains Buy on CareMax, Lowers Price Target to $6

UBS analyst Andrew Mok maintains CareMax (NASDAQ:CMAX) with a Buy and lowers the price target from $10 to $6.

byBenzinga Newsdesk

January 6, 2023

1 minute read

UBS analyst Andrew Mok maintains CareMax (NASDAQ:CMAX) with a Buy and lowers the price target from $10 to $6.

Why Cracker Barrel Shares Are Trading Lower By Around 13%? Here Are 42 Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

December 2, 2:27 PM

Gainers Yunhong CTI Ltd. (NASDAQ: CTIB) rose 42% to $0.54 after dipping 56% on Thursday.

ASAN

Morgan Stanley Maintains Underweight on SVB Finl Gr, Raises Price Target to $190

By Benzinga Newsdesk

December 16, 10:23 AM

Morgan Stanley analyst Manan Gosalia maintains SVB Finl Gr (NASDAQ:SIVB) with a Underweight and raises the price target from $186 to $190.

SIVB

Biden Says AI Companies ‘Must Earn Our Trust,’ Calls For ‘Responsible Innovation’

By Benzinga Neuro

May 22, 11:19 AM

Biden further added that he would do everything in his power to ensure the responsible use of AI, including AI-generated audio.

ProSomnus Announces Publication Of Four Accepted Abstracts In The Journal Of Dental Sleep Medicine In Advance Of Annual Meeting

By Happy Mohamed

April 18, 8:23 AM

ProSomnus, Inc. ("the Company") (NASDAQ:OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the publication of four abstracts in

OSA

UBS Maintains Buy on CareMax, Lowers Price Target to $6

Related Posts

Why Cracker Barrel Shares Are Trading Lower By Around 13%? Here Are 42 Stocks Moving In Friday’s Mid-Day Session

Morgan Stanley Maintains Underweight on SVB Finl Gr, Raises Price Target to $190

Biden Says AI Companies ‘Must Earn Our Trust,’ Calls For ‘Responsible Innovation’

ProSomnus Announces Publication Of Four Accepted Abstracts In The Journal Of Dental Sleep Medicine In Advance Of Annual Meeting